Saulė Gumauskaitė

Ms. Saulė Gumauskaitė

IPO Porto, Porto, Portugal
+1
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 June 2022 in Cancers
Verified
Journal Article
Open access
PDF file
NTNuno Tiago Tavares
Nuno Tiago Tavares
Saulė GumauskaitėSaulė Gumauskaitė
Saulė Gumauskaitė
João LoboJoão Lobo
João Lobo
Carmen JeronimoCarmen Jeronimo
Carmen Jeronimo
Rui HenriqueRui Henrique
Rui Henrique
Platinum-based chemotherapy is routinely used for the treatment of several cancers. Despite all the advances made in cancer research regarding this therapy and its mechanisms of action, tumor resistance remains a major concern, limiting its effectiveness. DNA methylation-based biomarkers may assist in the selection of patients that may benefit (or not) from this type of treatment and provide new targets to circumvent platinum chemoresistance, namely, through demethylating agents. We performed a systematic search of studies on biomarkers that might be predictive of platinum-based chemotherapy resistance, including in vitro and in vivo pre-clinical models and clinical studies using patient samples. DNA methylation biomarkers predictive of response to platinum remain mostly unexplored but seem promising in assisting clinicians in the generation of more personalized follow-up and treatment strategies. Improved methodologies for their detection and quantification, including non-invasively in liquid biopsies, are additional attractive features that can bring these biomarkers into clinical practice, fostering precision medicine.